Tab.3.
Composition of SLN formulation in the orthogonal design and result of the experiment
| Formulation composition effect | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MTZ (mg) | 5 | 5 | 5 | 5 | 15 | 15 | 15 | 15 | 25 | 25 | 25 | 25 | 35 | 35 | 35 | 35 |
| Phospholipids (mg) | 0 | 50 | 100 | 150 | 0 | 50 | 100 | 150 | 0 | 50 | 100 | 150 | 0 | 50 | 100 | 150 |
| GMS (mg) | 50 | 100 | 150 | 200 | 100 | 50 | 200 | 150 | 150 | 200 | 50 | 100 | 200 | 150 | 100 | 50 |
| Coemulsifiers (%) | 1 | 1.5 | 2 | 3 | 2 | 3 | 1 | 1.5 | 3 | 2 | 1.5 | 1 | 1.5 | 1 | 3 | 2 |
| Chitosan (mg/mL) | 1.5 | 2 | 2.5 | 3 | 3 | 2.5 | 2 | 1.5 | 2 | 1.5 | 3 | 2.5 | 2.5 | 3 | 1.5 | 2 |
| EE% | 29.30 | 60.80 | 58.90 | 56.50 | 62.40 | 57.20 | 48.00 | 54.00 | 42.90 | 41.80 | 70.00 | 58.40 | 24.00 | 36.50 | 58.70 | 76.90 |
| score | 1 | 6 | 5 | 5 | 6 | 5 | 3 | 4 | 2 | 2 | 8 | 5 | 1 | 1 | 5 | 9 |
| DL% | 1.01 | 2.05 | 1.29 | 0.77 | 6.59 | 4.81 | 2.12 | 2.16 | 4.04 | 1.90 | 8.09 | 4.75 | 3.80 | 4.61 | 6.97 | 10.96 |
| score | 1 | 2 | 1 | 1 | 6 | 4 | 2 | 2 | 4 | 1 | 8 | 4 | 3 | 4 | 6 | 10 |
| Diameter | 275.2 | 347.5 | 433.7 | 556.1 | 393.3 | 294.6 | 542.8 | 448.7 | 268.2 | 382.5 | 547.9 | 325.3 | 414.0 | 450.1 | 354.2 | 311.6 |
| score | 8 | 6 | 2 | 1 | 4 | 8 | 1 | 2 | 9 | 4 | 1 | 6 | 3 | 1 | 5 | 7 |
| Zeta potential |
19.3 | 14.4 | 13.0 | 12.0 | 18.3 | 19.4 | 6.4 | 9.3 | 10.3 | 9.4 | 7.6 | 14.2 | 24.6 | 10.6 | 6.7 | 11.6 |
| score | 6 | 4 | 3 | 3 | 6 | 7 | 1 | 1 | 2 | 1 | 1 | 4 | 9 | 2 | 1 | 2 |
| Sum | 5.1 | 4.8 | 2.9 | 2.6 | 5.4 | 6.6 | 1.5 | 2.0 | 4.3 | 2.1 | 3.1 | 4.8 | 5.0 | 1.7 | 3.5 | 5.7 |
MTZ: methazolamide; GMS: glyceryl monostearate; EE: entrapment efficiency; DL: drug loading.